Related coverage linked through entity extraction aliases.
Apr 22, 2026
Novartis reported 2025 sales of $54.5 billion, up 8%, while earnings per share rose 15% to $8.98. Amarin reported fiscal 2025 revenue of $213.6 million, down 6.5%, and narrowed its net loss per share to $0.09 from $0.20.
Feb 19, 2026
Novartis commits $23 billion to U.S. manufacturing expansion with new facilities in North Carolina, California, and Florida, while advancing its immunoglobulin A nephropathy drug portfolio with positive Phase III results for Vanrafia.
Feb 16, 2026
Novartis announced final Phase III ALIGN trial results showing Vanrafia (atrasentan) slowed kidney function decline in adults with IgA nephropathy, with a 2.39ml/min/1.73m² eGFR difference versus placebo at week 136.
Feb 13, 2026
Novartis announced final Phase III ALIGN results showing Vanrafia slowed kidney function decline in adults with IgA nephropathy, supporting planned submissions for traditional approval in 2026 following accelerated approvals in the U.S. and China in 2025.
